Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Neuren Pharmaceuticals Limited (NEU) Share Price & Analysis

NEU Stock Chart & Stats

A$20.36A$0.22(1.09%)
At close: 4:00 PM GMT+11
AUD 17.5AUD 20AUD 22.53 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
AUD 20.24 - AUD 20.70
52-Week Range
AUD 11.00 - AUD 23.76
Previous Close
AUD 20.14
Volume
311.36K
Average Volume (3M)
317.18K
Market Cap
AUD 2.58B
Enterprise Value
AUD 1.97B
Total Cash (Recent Filing)
AUD 286.54M
Total Debt (Recent Filing)
AUD 0
Price to Earnings (P/E)
128.6
Beta
2.58
Next Earnings
Feb 24, 2027 (Est.)
EPS Estimate
0.28
Last Dividend Ex-Date
Sep 15, 2026
Dividend Yield
0.74%

Bulls Say, Bears Say

Bulls Say

Debt-Free Balance Sheet

A large cash balance and debt-free structure give Neuren the capacity to fund NNZ-2591 development and corporate needs internally, reducing dilution risk and preserving flexibility through clinical and regulatory cycles.

DAYBUE Royalty Growth

Neuren benefits from an asset-light royalty model tied to an approved therapy. Rising DAYBUE sales, broader adoption and European and Japanese expansion can support recurring royalties and future milestone receipts.

Pipeline Optionality

Progressing NNZ-2591 into Phase III creates a meaningful second value driver beyond DAYBUE royalties. Success in rare pediatric disorders could expand Neuren’s partnered revenue base and support additional licensing opportunities.

Bears Say

Revenue Volatility

Despite high margins and recent profitability, uneven revenue performance reduces visibility into earnings durability. Dependence on partner milestones and commercial timing may produce fluctuations that complicate long-term financial planning.

HIE Regulatory Delay

The additional study delays clinical entry and extends the time before HIE can contribute to the pipeline. It also demonstrates that regulatory requirements can materially lengthen development timelines and increase program costs.

Koala Execution Risk

A complex placebo-controlled Phase III design and reliance on two co-primary endpoints increase execution risk. Slower recruitment or an unfavorable result could defer or reduce the commercial value of NNZ-2591.

Neuren Pharmaceuticals Limited News

NEU FAQ

What was Neuren Pharmaceuticals Limited’s price range in the past 12 months?
Neuren Pharmaceuticals Limited lowest share price was AU$11.00 and its highest was AU$23.76 in the past 12 months.
What is Neuren Pharmaceuticals Limited’s market cap?
Neuren Pharmaceuticals Limited’s market cap is AU$2.58B.
When is Neuren Pharmaceuticals Limited’s upcoming earnings report date?
Neuren Pharmaceuticals Limited’s next earnings report is estimated for Feb 24, 2027 (not yet confirmed), which is in 115 days.
How were Neuren Pharmaceuticals Limited’s earnings last quarter?
Neuren Pharmaceuticals Limited released its earnings results on Aug 25, 2026. The company reported AU$0.038 earnings per share for the quarter, missing the consensus estimate of AU$0.089 by -AU$0.051.
Is Neuren Pharmaceuticals Limited overvalued?
According to Wall Street analysts Neuren Pharmaceuticals Limited’s price is currently Undervalued.
Does Neuren Pharmaceuticals Limited pay dividends?
Neuren Pharmaceuticals Limited pays a ― dividend of AU$0.15 which represents an annual dividend yield of 0.74%. See more information on Neuren Pharmaceuticals Limited dividends here
What is Neuren Pharmaceuticals Limited’s EPS estimate?
Neuren Pharmaceuticals Limited’s EPS estimate is 0.28.
How many shares outstanding does Neuren Pharmaceuticals Limited have?
Neuren Pharmaceuticals Limited has 126,773,980 shares outstanding.
What happened to Neuren Pharmaceuticals Limited’s price movement after its last earnings report?
Neuren Pharmaceuticals Limited reported an EPS of AU$0.038 in its last earnings report, missing expectations of AU$0.089. Following the earnings report the stock price went down -10.565%.
Which hedge fund is a major shareholder of Neuren Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:NEU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology